Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study examines the effect of treatment of levodopa/entacapone on quality of life, as measured by the Parkinson's Disease-Questionnaire 8 (PDQ-8), in Parkinson's disease patients with no or minimal, non-disabling motor fluctuations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Carbidopa; Carbidopa, levodopa drug combination; Entacapone; Levodopa

Criteria

Inclusion Criteria:

• Clinical diagnosis of idiopathic Parkinson's disease exhibiting at least 2 or 3 symptoms

• Motor functions must be regarded as non-disabling by the patient

Exclusion Criteria:

• History, signs or symptoms suggesting the diagnosis of atypical or secondary parkinsonism

• History of dyskinesia

• Previous or current use of entacapone or tolcapone

• Unstable Parkinson's disease patients requiring/receiving regimens of levodopa

• Subjects taking levodopa/DDCI controlled release or extended release formulations